Impact of New Pharmaceutical Policies on Insurance Compliance and Strategy
On May 5, 2026, the White House Council of Economic Advisers released a report forecasting potential savings from the Most Favored Nation (MFN) drug pricing policy. The Trump administration is advocating for this policy to be legislated by Congress, with discussions underway to explore its ramifications, particularly on international markets. These debates highlight the importance of regulatory compliance and risk management in the insurance landscape.
On May 13, 2026, the Department of Commerce detailed new procedures in the Federal Register for pharmaceutical manufacturers interested in applying for company-specific agreements to produce domestically. This initiative aims to grant eligibility for reduced Section 232 duty rates on imports of certain pharmaceutical products and their ingredients, impacting both underwriting and regulatory strategies within insurance sectors related to pharmaceuticals.
Legal Challenges and Regulatory Reviews
Legal challenges against the Inflation Reduction Act's drug pricing-negotiation program remain ongoing. Currently, the proposed rule for the initial price applicability year 2029 is transitioning from guidance to formal regulation. It is under review by the Office of Management and Budget, with various stakeholders, including payers and providers, engaging in discussions with the Centers for Medicare & Medicaid Services (CMS).
Some pharmaceutical manufacturers now require covered entities to provide claims-level data for all 340B program dispenses, including those from in-house pharmacies. These data-sharing requirements are subject to intense debate among stakeholders, highlighting increased transparency demands within the insurance industry.
HRSA Policies and Litigation
During the COVID-19 pandemic, the Health Resources & Services Administration (HRSA) had relaxed certain registration requirements for child sites of covered entities. The subsequent removal of this waiver in 2023 led to ongoing litigation, with HRSA filing an appeal following a District Court decision. This underscores the evolving landscape of regulatory compliance and the legal challenges insurers must navigate.
Two lawsuits remain concerning HRSA's policies for certifying STD clinics in the 340B program. One involves manufacturers, while the other involves covered entities challenging HRSA's termination of certain STD clinics from the program. The US District Court for the District of Columbia recently upheld these terminations, continuing to shape the regulatory environment.
HRSA has revised its Administrative Dispute Resolution website, offering new summaries of decisions, particularly those involving claims of overcharges by manufacturers against covered entities. Legal disputes over state-enacted 340B regulations continue, with Virginia's General Assembly establishing a Prescription Drug Affordability Board, despite gubernatorial challenges. These developments in legal and regulatory domains are crucial for insurers focused on compliance and claims management.